Stock Groups

U.S. CDC advisers recommend COVID-19 vaccine boosters for 65 and older, high risk By Reuters

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: Yomaria de Santiago (35), a student at Cal State Dominguez Hills, is given a Pfizer BioNTech coronavirus vaccine (19COVID-19) shot in Carson, Los Angeles. This was on August 26, 2021. REUTERS/Lucy Nicholson

(Reuters) – A U.S. Centers for Disease Control and Prevention advisory panel on Thursday recommended a booster shot of the Pfizer (NYSE:) and BioNTech COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions.

After approval by U.S. Food and Drug Administration, the vote of the group allows for the booster rollout to start as early as this week for millions who received their second dose less than six months ago.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs include futures, stocks, indexes and Forex. Prices are provided not by the exchanges. They are set by market makers. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]